IP Library Granted Patent US 7,160,983
Granted Patent B2
US 7,160,983 · App. 10/666,072 · Granted Jan 9, 2007

Echinocandin derivatives, their method of preparation and their application as anti-fungal agents

Assignee: Aventis Pharma S.A.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,160,983
App. No.
10/666,072
Granted
Jan 9, 2007
Kind
B2
Abstract

Compound of the formula wherein R 2 is —CH 2 —CH 2 —NH 2 , R 3 is —CH 3 , R 4 is —OH, R is Z is methyl and salts thereof which are useful as antifungal agents.

Claims (13)

1. A compound of the formula:

wherein R is

or a pharmaceutically acceptable acid addition salt thereof.

2. A pharmaceutical composition comprising a compound of claim 1 or a pharmaceutically acceptable acid addition salt thereof and a pharmaceutically acceptable carrier.

3. The method of claim 2 in which said pharmaceutically acceptable carrier comprises apyrogenic sterile water.

4. The pharmaceutical composition of claim 2 which is in the form of a sugar coated tablet, capsule, granule, suppository, injectable preparation, ointment, cream or gel.

5. A method of treating an ailment caused by exposure to a fungus comprising administering to a person in need thereof a pharmaceutical composition according to claim 2 .

6. A method of treating an ailment in a person caused by exposure to a fungus comprising administering to a person in need thereof an antifungally effective amount of a compound of claim 1 .

7. The method of claim 6 in which said fungus is selected from the group consisting of Candida albicans, Candida glabrate, Candida krusei, Candida tropicalis, Candida pseudotropicalis, porapsilosis, Aspergillus fumigatus, Aspergillus flavus , and Cryptococcus neoformans.

8. The method of claim 6 in which said ailment is selected from the group consisting of digestive, urinary, vaginal or cutaneous candidoses, cryptococcoses, neuromenengeal, pulmonary or cutaneous cryptococcoses, bronchopulmonary and pulmonary aspergilloses and invasive aspergilloses in an immunocompromised subject.

9. The method of claim 6 which is directed to the treatment of mycosic ailments in people with congenital or acquired immune compromise.

10. The method of claim 6 in which the effective amount ranges from about 50 mg to about 300 mg per day.

11. A method of treating an ailment caused by exposure to a fungus comprising administering to a person in need thereof an antifungally effective amount of a compound of claim 1 .

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 27, 2006
From: AVENTIS PHARMA S.A.
To: NOVEXEL
Reel/Frame 018545/0842 →
Priority Claims (2)
FR 97 15628 · Dec 10, 1997 · national
FR 98 13361 · Oct 26, 1998 · national
Continuity (2)
Division 0958145100
Related Publication 20040072737A1 · Apr 15, 2004